<DOC>
	<DOCNO>NCT01312857</DOCNO>
	<brief_summary>The purpose study see Panitumumab plus treatment increase time remission . Remission mean sign cancer .</brief_summary>
	<brief_title>Study Hepatic Arterial Infusion With Intravenous Irinotecan , 5FU Leucovorin With Without Panitumumab , Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>History histologically confirm colorectal adenocarcinoma metastatic liver clinical radiographic evidence extrahepatic disease . Confirmation diagnosis must perform MSKCC . Completely resect hepatic metastasis without current evidence metastatic disease . Lab value ≤ 14 day prior registration : WBC ≥ 3.0 K/uL ANC &gt; 1.5 K/uL Platelets ≥ 100,000/uL Creatinine &lt; 1.5 mg/dL HGB ≥ 9 gm/dL Renal function ( ≤ 14 day prior registration ) . Creatinine ≤1.5 mg/dL creatinine clearance ≥ 50 mL/min calculate CockcroftGault method follow : Male creatinine clearance = ( 140 age year ) x ( weight Kg ) / ( serum Cr mg/dl x 72 ) Female creatinine clearance = ( 140 age year ) x ( weight Kg ) x 0.85 / ( serum Cr mg/dl x 72 ) ( use creatinine clearance per protocol base chemotherapy regimen ) Hepatic function , follow : ( ≤ 14 day prior registration ) Aspartate aminotransferase ( AST ) ( ≤ 5 x ULN ) Alanine aminotransferase ( ALT ) ( ≤ 5 x ULN ) Total Bilirubin ≤ 1.5 mg/dl Magnesium ≥ low limit normal ( ≤ 48 hour prior registration . ) Calcium ≥ low limit normal ( ≤ 48 hour prior registration . ) Prior chemotherapy acceptable last dose give ≥ 3 week prior registration study . [ Note : chemotherapy give resection liver lesion prior treatment study . ] Any investigational agent acceptable administer ≤ 30 day registration KPS ≥ 60 % ( ECOG ( Karnofsky ) performance status ( preferably 0 1/≥ 60 % Karnofsky ) Histologically confirm RAS wild type . Paraffinembedded tumor tissue obtain primary tumor metastasis Patients &lt; 18 year age . Prior radiation liver ( Prior radiation therapy pelvis acceptable complete least 4 week prior registration . ) Active infection , ascites , hepatic encephalopathy . Prior treatment HAI FUDR . Patients prior anti EGFR antibody therapy inhibitor respond treatment exclude . However , patient respond prior antiEGFR therapy eligible . ) Female patient pregnant lactate plan become pregnant within 6 month end treatment ( female patient childbearing potential must negative pregnancy test ≤ 72 hour registration ) . If patient serious medical problem may preclude receive type treatment . Patients current evidence hepatitis A , B , C ( ie , active hepatitis ) Patients history know presence primary CNS tumor , seizure well control standard medical therapy , history stroke also exclude . History allergic reaction attribute compound similar chemical biologic composition Panitumumab . Serious nonhealing active wound , ulcer , bone fracture . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . Patients diagnosis Gilbert 's disease . History malignancy , except : Malignancy treat curative intent know active disease present ≥ 3 year prior registration felt low risk recurrence treat physician Adequately treat nonmelanomatous skin cancer lentigo maligna without evidence disease Adequately treat cervical carcinoma situ without evidence disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>colon</keyword>
	<keyword>rectal</keyword>
	<keyword>liver</keyword>
	<keyword>AMG 954 ( Panitumumab )</keyword>
	<keyword>DEXAMETHASONE</keyword>
	<keyword>FLOXURIDINE</keyword>
	<keyword>FLUOROURACIL</keyword>
	<keyword>IRINOTECAN ( CPT-11 ) CAMPTOSAR</keyword>
	<keyword>LEUCOVORIN</keyword>
	<keyword>10-137</keyword>
</DOC>